title: MHC class II-restricted presentation of native protein antigen by B cells is inhibitable by cycloheximide and brefeldin A.
abstract: The presentation of protein Ag with MHC class II proteins involves the uptake of the protein Ag by endocytosis followed by processing, probably proteolysis, in an intracellular acidic compartment. However, there remains considerable controversy as to the precise route taken by the antigen and the MHC class II protein during this process. The unusual stability of Ag-MHC class II protein complexes has led to speculation that antigen can only associate with newly synthesized MHC class II molecules. An alternate possibility is that the MHC class II binding site can be regenerated within the cell during internalization and recycling of MHC class II proteins. To address these possibilities, three different murine B lymphoma lines were tested for their ability to process and present native protein Ag in the presence of the protein synthesis inhibitor cycloheximide or the protein synthesis inhibitor cycloheximide or the protein export inhibitor, Brefeldin A. Both agents blocked the presentation of native OVA or native hen egg lysozyme to Ag-specific T cell hybridomas. No effect was seen on peptide presentation or on presentation to allo- or autoreactive T cells. Inasmuch as Brefeldin A has been previously shown to block protein export without affecting protein internalization or protein degradation in the endocytic pathway, the simplest interpretation of these data is that antigenic fragments generated in the APC after uptake by the endocytic pathway, preferentially associate with newly synthesized rather than mature MHC class II proteins.
authors.affiliation: Department of Immunology, University of Toronto, Ontario.
authors.forename: Y
authors.initials: Y
authors.lastname: St-Pierre
authors.forename: T H
authors.initials: TH
authors.lastname: Watts
mesh_terms: D000818:Animals; D000938:Antigen-Presenting Cells / Q000187:drug effects*; D001402:B-Lymphocytes / Q000276:immunology*; D020126:Brefeldin A; D003513:Cycloheximide / Q000494:pharmacology*; D003517:Cyclopentanes / Q000494:pharmacology*; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D007376:Interleukin-2 / Q000096:biosynthesis; D051379:Mice; D008807:Mice, Inbred BALB C; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D003517:Cyclopentanes; D000949:Histocompatibility Antigens Class II; D007376:Interleukin-2; D011500:Protein Synthesis Inhibitors; D020126:Brefeldin A; D003513:Cycloheximide